Trial description
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk
Contact name
Dr Kate Fife
Trial start date
Friday, December 6, 2019
Trial end date
Saturday, March 1, 2025
Trial tumour type
Show on Radiotherapy